Lori Payton, Chief Development Officer of Yarrow Bioscience, Inc., filed a statement of changes in beneficial ownership on October 30, 2026, reporting the acquisition of a stock option covering 99,827 shares of common stock with a transaction date of October 29, 2026.

Key Highlights

  • Reporting person and role: Lori Payton, Chief Development Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW)
  • Security acquired: A stock option (right to buy) covering 99,827 shares of common stock
  • Exercise price: $20 per share, with the derivative security priced at $0
  • Transaction date: October 29, 2026; option expiration date is October 29, 2036
  • Vesting schedule: One quarter vests on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service
  • Beneficial ownership following transaction: 99,827 derivative securities held directly

Stock Option Award to Yarrow Bioscience Chief Development Officer Lori Payton

According to the filing, Lori Payton, serving as Chief Development Officer at Yarrow Bioscience, Inc., a bioscience company listed on NASDAQ under the ticker YARW, acquired a stock option granting the right to purchase 99,827 shares of the issuer's common stock. The transaction was coded as an acquisition and was reported with a transaction date of October 29, 2026. The option carries an exercise price of $20 per share and is set to expire on October 29, 2036, giving it a ten-year term from the grant date.

The filing discloses that the option's vesting is contingent on Payton's continued service to Yarrow Bioscience. Specifically, one quarter of the 99,827 shares subject to the option will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the three years that follow. Following the reported transaction, Payton directly holds 99,827 derivative securities, as disclosed in Table II of the filing. The form was signed by Tyler Zeronda as attorney-in-fact for Lori Payton and filed on October 30, 2026.

No transactions were reported in Table I, which covers non-derivative securities. The filing was made by one reporting person and was not identified as an amendment to a prior submission. No Rule 10b5-1(c) plan designation was indicated in the filing for this transaction.

What Was Disclosed

Yarrow Bioscience's Chief Development Officer Lori Payton reported acquiring a stock option to purchase 99,827 shares of common stock at $20 per share, expiring October 29, 2036, with a vesting schedule tied to continued service through approximately four years from grant.